Technical Analysis for DAWN - Day One Biopharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 14.92 | 12.94% | 1.71 |
DAWN closed up 12.94 percent on Friday, April 26, 2024, on 3.29 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Fell Below 20 DMA | Bearish | 12.94% | |
| Fell Below 200 DMA | Bearish | 12.94% | |
| MACD Bearish Centerline Cross | Bearish | 12.94% | |
| MACD Bearish Signal Line Cross | Bearish | 12.94% | |
| Volume Surge | Other | 12.94% |
| Alert | Time |
|---|---|
| 3x Volume Pace | 1 day ago |
| 20 DMA Resistance | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| Rose Above 20 DMA | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.85 |
| 52 Week Low | 9.67 |
| Average Volume | 1,094,511 |
| 200-Day Moving Average | 13.56 |
| 50-Day Moving Average | 15.20 |
| 20-Day Moving Average | 14.82 |
| 10-Day Moving Average | 14.94 |
| Average True Range | 1.17 |
| RSI (14) | 50.00 |
| ADX | 18.55 |
| +DI | 24.76 |
| -DI | 20.66 |
| Chandelier Exit (Long, 3 ATRs) | 13.87 |
| Chandelier Exit (Short, 3 ATRs) | 16.54 |
| Upper Bollinger Bands | 16.54 |
| Lower Bollinger Band | 13.09 |
| Percent B (%b) | 0.53 |
| BandWidth | 23.31 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0068 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.73 | ||||
| Resistance 3 (R3) | 17.47 | 16.29 | 17.26 | ||
| Resistance 2 (R2) | 16.29 | 15.57 | 16.41 | 17.10 | |
| Resistance 1 (R1) | 15.60 | 15.13 | 15.95 | 15.86 | 16.95 |
| Pivot Point | 14.42 | 14.42 | 14.59 | 14.54 | 14.42 |
| Support 1 (S1) | 13.73 | 13.70 | 14.07 | 13.98 | 12.89 |
| Support 2 (S2) | 12.55 | 13.26 | 12.67 | 12.74 | |
| Support 3 (S3) | 11.86 | 12.55 | 12.58 | ||
| Support 4 (S4) | 12.11 |
